CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 4, July/August 2021
AFRICA
181
number of studies and clinical practice that NLR serves as
an evaluation index for diagnosis and prognosis of patients with
cardiac insufficiency.
11
Determining NLR in plasma in patients
with CHF and AF has been a subject of study in recent years. It is
currently believed that NLR is an ideal marker of myocardial injury,
and the level has a significant positive correlation with the degree of
myocardial injury.
12
NLR has predictive value for the prognosis of a variety of
cardiovascular diseases.
13
Patients with coronary heart disease have
a higher NLR in plasma.
14
Furthermore, NLR in plasma is higher
in patients with acute myocardial infarction than that in patients
with unstable angina, while it is also higher in the latter than
that in patients with stable angina. After correcting for a variety
of traditional cardiovascular risk factors, NLR can be used as a
predictor for major adverse events of AF.
15
In our study, the results
of logistic regression analysis showed that NLR was an independent
predictive factor for MACE in patients with CHF and AF.
In our study, the patients were divided into four groups based on
the quartile of NLR. It was found that the difference in incidence
of MACE was statistically significant between the four groups (
p
< 0.05), manifesting as increased incidence of acute myocardial
infarction, severe arrhythmia and cardiac death with increasing
NLR. AF raises both resting heart rate and response heart
rate, further reducing cardiac output and elevating cardiac filling
pressure, which is the internal cause of aggravation of HF by AF
and an important factor causing acute myocardial infarction.
16
AF is
a common type of arrhythmia, and CHF can further enhance atrial
depolarisation and repolarisation dispersion and cause re-entry
more easily, thereby leading to severe arrhythmia.
17
In this study, according to the analysis results of Kaplan–Meier
survival curves, the duration of MACE in group D was significantly
shorter than that in groups A and B. Yýlmaz
et al
. demonstrated
that NLR > 3.08 was an independent predictor of new-onset
myocardial infarction and in-hospital death in patients with HF.
18
In our study, the ROC curves showed that the optimal cut-off value
and area under the curve of NLR for MACE in patients with CHF
and AF were 3.12 and 0.879, respectively, confirming their high
diagnostic value.
Conclusion
NLR was an independent predictive factor for MACE in these
patients with CHF and AF, and it had high diagnostic value, which
is of importance for adopting the appropriate therapeutic regimen
and improving prognosis as early as possible.
This study was financially supported by Xintai Research and Development
Project (No 2020ZC272).
References
1.
Fontana J, Zima M, Vetvicka V. Biological markers of oxidative stress
in cardiovascular diseases: after so many studies, what do we know?
Immunol Invest
2018;
47
(8): 823–843.
2.
Ayesta A, Martinez-Selles H, de Luna AB,
et al.
Prediction of sudden
death in elderly patients with heart failure.
J Geriatr Cardiol
2018;
15
(2):
185–192.
3.
Yalcinkaya E, Yuksel UC, Celik M,
et al.
Relationship between neutro-
phil-to-lymphocyte ratio and electrocardiographic ischemia grade in
STEMI.
Arq Bras Cardiol
2015;
104
(2): 112–119.
4.
Awad F, Assrawi E, Jumeau C,
et al.
Impact of human monocyte and
macrophage polarization on NLR expression and NLRP3 inflamma-
some activation.
Plos One
2017;
12
(4): e0175336.
5.
Shang X, Xiao S, Dong N,
et al.
Assessing right ventricular function
in pulmonary hypertension patients and the correlation with the New
York Heart Association (NYHA) classification.
Oncotarget
2017;
8
(52):
90421.
6.
Zhu Q, Xiao W, Bai Y,
et al.
The prognostic value of the plasma
N-terminal pro-brain natriuretic peptide level on all-cause death and
major cardiovascular events in a community-based population.
Clin
Interv Aging
2016;
11
: 245–253.
7.
Richards AM, Troughton RW. Use of natriuretic peptides to guide and
monitor heart failure therapy.
Clin Chem
2012;
58
(1): 62–71.
8.
Guan P, Liang Y, Wang N. Fasudil alleviates pressure overload-induced
heart failure by activating Nrf2-mediated antioxidant responses.
J Cell
Biochem
2018;
119
(8): 6452–6460.
9.
Tahto E, Jadric R, Pojskic L,
et al.
Neutrophil-to-lymphocyte ratio and
its relation with markers of inflammation and myocardial necrosis in
patients with acute coronary syndrome.
Med Arch
2017;
71
(5): 312–315.
10. Yan W, Li JZ, He KL. The relationship between neutrophil-to-lympho-
cyte ratio and major cardiovascular events in elderly patients with
chronic heart failure.
J Geriatr Cardiol
2017;
14
(12): 780.
11. Budzianowski J, Pieszko K, Burchardt P,
et al.
The role of hematologi-
cal indices in patients with acute coronary syndrome.
Dis Markers
2017;
2017
: 3041565.
12. Durmu
ş
G, Belen E, Can MM. Increased neutrophil to lymphocyte ratio
predicts myocardial injury in patients undergoing non-cardiac surgery.
Heart Lung
2018;
47
(3): 243–247.
13. Zhang S, Diao J, Qi CM,
et al.
Predictive value of neutrophil to lympho-
cyte ratio in patients with acute ST segment elevation myocardial infarc-
tion after percutaneous coronary intervention: a meta-analysis.
BMC
Cardiovasc Disord
2018;
18
(1): 75.
14. Wang X, Fan X, Ji S,
et al.
Prognostic value of neutrophil to lymphocyte
ratio in heart failure patients.
Clin Chim Acta
2018;
485
: 44–49.
15. Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in
STEMI: a meta-analysis.
Eur J Clin Invest
2020; e13386.
16. Verdoia M, Barbieri L, Di Giovine G,
et al.
Neutrophil to lymphocyte
ratio and the extent of coronary artery disease: results from a large
cohort study.
Angiology
2016;
67
(1): 75–82.
17. Wändell P, Carlsson AC, Holzmann MJ,
et al.
The association between
relevant co-morbidities and prevalent as well as incident heart failure in
patients with atrial fibrillation. J
Cardiol
2018;
72
(1): 26–32.
18. Yýlmaz S, Canpolat U, Baþer K,
et al.
Neutrophil-to-lymphocyte ratio
predicts functionally significant coronary artery stenosis in patients
with stable coronary artery disease.
Arch Turk Soc Cardiol
2018;
46
(2):
129–135.